Although young cancer survivors face an elevated risk for later developing cervical, oropharyngeal, and several other human papillomavirus (HPV)–related cancers, HPV vaccination rates among this group remain low. This is primarily because of certain vaccine‐related concerns, according to a study published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.
To understand why young cancer survivors often opt out of HPV vaccination—which is highly effective in preventing infection with the HPV types most commonly associated with cancer—Brooke Cherven, PhD, MPH, RN, CPON, a researcher at Winship Cancer Institute of Emory University and the Aflac Cancer & Blood Disorders Center of Children’s Healthcare of Atlanta and Emory University, and assistant professor in the Department of Pediatrics at the Emory University School of Medicine, and her colleagues analyzed data from an open-label clinical trial of the HPV vaccine among cancer survivors who were 9–26 years old and 1–5 years from the completion of their cancer treatment. Survivors (or their parents) who declined participation in the trial were asked their reasons for declining.
Among 301 survivors who declined participation in the clinical trial, 215 (71.4%) did so for reasons related to the HPV vaccine. Some of these reasons were similar to those reported in the general population, including concerns about vaccine safety (such as “hearing bad things about the vaccine”), importance (such as viewing the vaccine as “unnecessary”), and timing (such as parents preferring to wait to vaccinate until their child is older). Some survivors also expressed issues specific to cancer survivorship, including preoccupation with health conditions related to their previous cancer treatment, concerns that they had already “been through so much” and wished to avoid further medical interventions, and guidance from a healthcare provider to delay or decline the vaccine “because of all the treatment he’s had.”
Findings from this study may help health care providers—both oncologists and primary care clinicians—address many of the concerns that patients and their families have about HPV vaccination.
“The HPV vaccine is an important tool for cancer prevention, particularly for the vulnerable population of cancer survivors,” said Dr. Cherven. “By incorporating messages that address common concerns, health care providers may feel more prepared and confident when recommending the HPV vaccine to survivors in their practice.”
Additional Information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. A free abstract of this article will be available via the CANCER Newsroom upon online publication. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, [email protected]
Full Citation:
“Reasons for refusal of the human papillomavirus vaccine among young cancer survivors.” Brooke Cherven, James L. Klosky, K. Elizabeth Keith, Melissa M. Hudson, Smita Bhatia, and Wendy Landier. CANCER; Published Online: December 19, 2022 (DOI: 10.1002/cncr.34521).
URL Upon Publication: http://doi.wiley.com/10.1002/cncr.34521
Author Contact: Jenny Owen, Chief Marketing and Communications Officer at the Winship Cancer Institute of Emory University, at [email protected] or +1 404-778-8117.
About the Journal
CANCER is a peer-reviewed publication of the American Cancer Society integrating scientific information from worldwide sources for all oncologic specialties. The objective of CANCER is to provide an interdisciplinary forum for the exchange of information among oncologic disciplines concerned with the etiology, course, and treatment of human cancer. CANCER is published on behalf of the American Cancer Society by Wiley and can be accessed online. Follow us on Twitter @JournalCancer.
About Wiley
Wiley is one of the world’s largest publishers and a global leader in scientific research and career-connected education. Founded in 1807, Wiley enables discovery, powers education, and shapes workforces. Through its industry-leading content, digital platforms, and knowledge networks, the company delivers on its timeless mission to unlock human potential. Visit us at Wiley.com. Follow us on Facebook, Twitter,LinkedIn and Instagram.
The Editorial Team at Healthcare Business Today is made up of skilled healthcare writers and experts, led by our managing editor, Daniel Casciato, who has over 25 years of experience in healthcare writing. Since 1998, we have produced compelling and informative content for numerous publications, establishing ourselves as a trusted resource for health and wellness information. We offer readers access to fresh health, medicine, science, and technology developments and the latest in patient news, emphasizing how these developments affect our lives.